Five-Year Results From the NATALEE Trial: Evaluating Ribociclib in Early Breast Cancer

Welcome back to another Pharmacy Times Peer Exchange series. In this episode titled, Seven-Year Outcomes From the monarchE Trial: Long-Term Efficacy and Safety of Abemaciclib in Early Breast Cancer, Dr. Rose DiMarco led the conversation about the following questions:

What was the patient population studied in this trial and what was the study design?

How were the outcomes such as overall survival, invasive disease-free survival, and distant relapse-free survival defined and how are these applicable to clinical practice?

What was the key efficacy data seen in this trial?

Drs. Heather Moore and Julia Zeigengeist highlighted the 7-year follow-up data from the monarchE trial, which evaluated the addition of abemaciclib to adjuvant endocrine therapy in patients with high-risk early breast cancer. Faculty reviewed the study population and trial design to contextualize how the results apply to real-world clinical practice. The discussion clarified key clinical endpoints—including invasive disease-free survival, distant relapse-free survival, and overall survival—and their relevance in evaluating long-term benefit. Experts examined the most important efficacy findings from the extended follow-up and what they reveal about durable treatment outcomes. The panel reviewed the long-term safety profile of abemaciclib and considerations for patient management. Finally, the faculty shared their perspectives on the most meaningful takeaways from the 7-year data. The discussion focused on how these findings may influence treatment decisions and patient selection in the adjuvant setting for e

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Five-Year Results From the NATALEE Trial: Evaluating Ribociclib in Early Breast Cancer, panelists will continue their discussion on early breast cancer and highlight the 5-year findings from the NATALEE trial, which evaluated ribociclib in combination with a nonsteroidal aromatase inhibitor for the treatment of early breast cancer. Faculty discussed the trial’s patient population, study design, efficacy and safety outcomes, and key takeaways, while also comparing these results with long-term data from the monarchE trial to highlight implications for clinical practice.